Associated Press
FILE - In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Thursday, Dec. 17, 2020, a panel of independent experts is meeting to discuss a vaccine made by Moderna. The panel s review for the Food and Drug Administration is the next-to-last step before the agency decides whether the shots can be used on an emergency basis. (AP Photo/Hans Pennink)
WASHINGTON The head of the Food and Drug Administration said late Thursday that his agency will move to quickly authorize the second COVID-19 vaccine to fight the pandemic, hours after the shot won the key endorsement of a government advisory panel.
Close
A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign. breaking editor s pick featured top story U.S. government advisory panel has endorsed second COVID-19 vaccine
By MATTHEW PERRONE and LAURAN NEERGAARD
Associated Press Dec 17, 2020
Dec 17, 2020
A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
WASHINGTON â A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
WASHINGTON (AP) The head of the Food and Drug Administration said late Thursday that his agency will move to quickly authorize the second COVID-19 vaccine to fight the pandemic, hours after the shot won the key endorsement of a government advisory panel.
FDA Commissioner Stephen Hahn said in a statement that regulators have communicated their plans to drugmaker Moderna, which co-developed the vaccine with the National Institutes of Health. The announcement came after a panel of FDA advisers, in a 20-0 vote, ruled that the benefits of the vaccine outweighed the risks for those 18 years old and up.
Once FDA s emergency use authorization is granted, Moderna will begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.
FILE - A man stands outside an entrance to a Moderna, Inc., building, Monday, May 18, 2020, in Cambridge, Mass. A second COVID-19 vaccine moved closer to joining the U.S. fight against the pandemic Thursday, Dec. 17, 2020 as government experts convened for a final public review of its safety and effectiveness. The shot from Moderna and the National Institutes of Health is urgently needed as the country continues to record ever-higher numbers of new cases, hospitalizations and deaths ahead of more holiday travel and family gatherings. FDA s OK is expected shortly after the all-day meeting concludes. (AP Photo/Bill Sikes, file) FILE - In this Monday, July 27, 2020 file photo, a nurse prepares a shot as a study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc., gets underway in Binghamton, N.Y. On Thursday, Dec. 17, 2020, a panel of independent experts is meeting to discuss a vaccine made by Moderna. The pan
US panel OKs Moderna COVID-19 vaccine for emergency authorization
By Matthew Perrone and Lauran Neergaard
The Associated Press
WASHINGTON A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign.
The Food and Drug Administration is expected to follow the recommendation and quickly OK the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0 vote, agreed the benefits of the vaccine outweighed the risks for those 18 years old and up.
Once emergency use authorization is granted, Moderna will begin shipping millions of doses, earmarked for health workers and nursing home residents, to boost the largest vaccination effort in U.S. history.